MINNEAPOLIS, Aug. 23, 2011 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ treatment catheters that provide a durable and effective procedure delivered in the comfort of a urologist's office for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for its fourth fiscal quarter and fiscal year 2011 ended June 30, 2011.
